Jim Mullen, Editas Medicine

Ex-Bio­gen CEO Jim Mullen steps back to the helm of a biotech, and once again he has a crit­i­cal chal­lenge to con­front

A decade af­ter he was pushed out of the top post at Bio­gen by a gang of ac­tivists, Jim Mullen is step­ping back up to the helm of a biotech — this time look­ing to make his­to­ry in gene edit­ing.

Ed­i­tas put out the word this morn­ing that Mullen, who has been chair­man of the com­pa­ny, will take the CEO po­si­tion as Cindy Collins steps aside on Feb­ru­ary 15. Mullen is the third CEO to run the com­pa­ny since he was named chair­man in 2018.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA